This site is intended only for healthcare professionals resident in Egypt
BROAD AGE INDICATION2
MenACWY-TT vaccine with demonstrated seroprotection and approved for use from age 6 weeks with no upper age limit
MenACWY-TT vaccine with antibody persistence evaluated for up to 10 years
MenACWY-TT vaccine shown to be immunogenic in immunocompromised population, like patients with anatomical or functional asplenia
Proven non-inferior to monovalent MenC vaccines
DOSING AND COADMINISTRATION2
Nimenrix® offers coadministration with other routine immunisations for infants, toddlers, and adolescents
Nimenrix® can be prepared and administered in a few easy steps
Safety has been evaluated in more than 10,000 individuals in clinical trials
Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.